Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2020 first-quarter earnings
Lede-What You Need to Know About Johnson & Johnson's 2020 First-Quarter Earnings.jpg

What you need to know about Johnson & Johnson’s 2020 first-quarter earnings

Check out this infographic breakdown of the company’s first-quarter 2020 performance, with key highlights from its pharmaceutical, consumer and medical devices businesses.

Inset - Quarterly Earnings Ribbon
Johnson & Johnson First Quarter 2020 Earnings infographic

This morning, Johnson & Johnson shared its first-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 132,000 employees across the globe working every day to help change the trajectory of health for humanity.

“We recognize the unfortunate impact that the COVID-19 pandemic has had on people, communities, businesses and the world. While Johnson & Johnson’s first quarter results were strong, reflecting the resiliency of our diversified business, that narrative has understandably taken a back seat to the more pressing concern of addressing COVID-19,” says Joseph Wolk, Executive Vice President, Chief Financial Officer. “We are not only confident in winning the fight against this public health crisis with efforts such as our collaboration to co-fund investment in vaccine development, but we also have confidence in the fundamentals of our entire business, which are remarkably strong for the long term.”

For more details about the company’s 2020 first-quarter results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic that highlights key stats.


Johnson & Johnson First Quarter 2020 Earnings infographic

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.